Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
American Journal of Cancer Research|January 8, 2021
Docosahexaenoic acid (DHA), an omega-3 fatty acid, inhibits tumor growth and metastatic potential of ovarian cancerLindsay West, Yajie Yin, Stuart R Pierce, et al.
Gynecologic Oncology|March 16, 2007
Outcomes in surgical stage I uterine papillary serous carcinomaLaura J Havrilesky, Angeles Alvarez Secord, Victoria Bae-Jump, et al.
Obstetrical & Gynecological Survey|August 13, 2014
Uterine morcellation at the time of hysterectomy: techniques, risks, and recommendationsJessica E Stine, Daniel L Clarke-Pearson, Paola A Gehrig
Cancer|March 11, 2025
The missing data: A review of gender and sex disparities in researchHannah C Karpel, Linda M Zambrano Guevara, B J Rimel, et al.
Gynecologic Oncology|June 30, 2009
A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancerAngeles Alvarez Secord, Laura J Havrilesky, David M O'Malley, et al.
Frontiers in Oncology|March 4, 2021
SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian CancerArthur-Quan Tran, Stephanie A Sullivan, Leo Li-Ying Chan, et al.
American Journal of Cancer Research|May 15, 2025
Onvansertib inhibits cell proliferation and increases sensitivity to paclitaxel in uterine serous cancer cellsJennifer G Haag, Xiaochang Shen, Nikita Sinha, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 12, 2014
Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancerRebecca Ann Previs, Joshua Kilgore, Renatta Craven, et al.
Molecular and Cellular Biology|April 19, 2017
VprBP/DCAF1 Regulates the Degradation and Nonproteolytic Activation of the Cell Cycle Transcription Factor FoxM1Xianxi Wang, Anthony Arceci, Kelly Bird, et al.
Annals of Surgical Oncology|November 6, 2020
Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?David Pierce Mysona, Sharad Ghamande, Jin-Xiong She, et al.
Pageof 8